ロード中...

Gefitinib (IRESSA) sensitive lung cancer cell lines show phosphorylation of Akt without ligand stimulation

BACKGROUND: Phase III trials evaluating the efficacy of gefitinib (IRESSA) in non-small cell lung cancer (NSCLC) lend support to the need for improved patient selection in terms of gefitinib use. Mutation of the epidermal growth factor receptor (EGFR) gene is reported to be associated with clinical...

詳細記述

保存先:
書誌詳細
主要な著者: Noro, Rintaro, Gemma, Akihiko, Kosaihira, Seiji, Kokubo, Yutaka, Chen, Mingwei, Seike, Masahiro, Kataoka, Kiyoko, Matsuda, Kuniko, Okano, Tetsuya, Minegishi, Yuji, Yoshimura, Akinobu, Kudoh, Shoji
フォーマット: Artigo
言語:Inglês
出版事項: BioMed Central 2006
主題:
オンライン・アクセス:https://ncbi.nlm.nih.gov/pmc/articles/PMC1698934/
https://ncbi.nlm.nih.gov/pubmed/17150102
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/1471-2407-6-277
タグ: タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!